Get Live Data

PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Shield Thera Share Price
  4. Shield Thera Share Regulatory News
  5. Eland Oil & Gas

Pin to quick picksShield Thera Regulatory News (STX)

Shield Thera Information

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.75
Bid: 1.70
Ask: 1.80
Change: 0.00 (0.00%)
Spread: 0.10 (5.882%)
Open: 1.75
High: 1.75
Low: 1.75
Prev. Close: 1.75
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Eland Oil & Gas

12 Dec 2019 17:30

RNS Number : 7391W
FTSE Russell
12 December 2019
 

 

 

 

 

Eland Oil & Gas (UK): Constituent DeletionChanges in FTSE UK Index Series

12 December 2019

Following the court sanctioning the scheme of arrangement in relation to the cash acquisition of Eland Oil & Gas (UK, constituent) by Seplat Petroleum Development Company (non-constituent), please see details of affected indexes and effective dates below:

 

Eland Oil & Gas (UK, B8HHWX6) will be deleted from the FTSE AIM 100 Index and the FTSE AIM UK 50 Index.

 

Shield Therapeutics (UK, BYV8129) will be added to the FTSE AIM 100 Index.

 

Warehouse REIT (UK, BD2NCM3) will be added to the FTSE AIM UK 50 Index.

 

All changes effective from 17 December 2019.

 

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSDMMMZVZNGLZM
123456789
Date   Source Headline
26th Jul 20197:00 amRNSFDA approves Feraccru® with a broad label
2nd Jul 201912:00 pmRNSAdditional Listing
13th Jun 20192:16 pmRNSResult of AGM
3rd Jun 20197:00 amRNSUpdate on Legal Proceedings
13th May 201912:00 pmEQSHardman & Co Research: Shield Therapeutics (STX): All in the execution
8th May 20197:00 amRNSAppointment of Joint Broker
2nd May 20197:00 amRNSInvestor presentation
1st May 201911:58 amRNSAdditional Listing
30th Apr 20197:00 amRNS2018 Annual Report and 2019 AGM Notice
26th Apr 20196:05 pmRNSPDMR Acquisition of Shares
24th Apr 20197:00 amRNSMajor extension to approval in Switzerland
17th Apr 20195:06 pmRNSGrant of share options
17th Apr 20195:01 pmRNSPDMR Acquisition of Shares and Additional Listing
17th Apr 20194:56 pmRNSPDMR Acquisition of Shares
11th Apr 20194:40 pmRNSHolding(s) in Company
8th Apr 20193:42 pmRNSAdditional Listing
3rd Apr 20197:00 amRNSFinal Results
1st Apr 20195:44 pmRNSAdditional Listing
1st Apr 201912:00 pmRNSChange of Adviser
27th Mar 20197:00 amRNSNotice of Results
14th Mar 20193:31 pmRNSPositive decision on Feraccru®'s process patent
4th Mar 20197:00 amRNSPositive results for Feraccru® in AEGIS-H2H study
29th Jan 20197:00 amRNSPositive results of AEGIS-CKD study
28th Jan 20197:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24th Jan 20197:00 amRNSBusiness and trading update
23rd Jan 201910:19 amRNSInvestor presentations
22nd Jan 20197:00 amRNSAppointment of Chairman
13th Dec 20187:00 amRNSUS New Drug Application PDUFA date for Feraccru
5th Dec 201810:04 amRNSUK launch of Feraccru® by Norgine
3rd Dec 20187:00 amRNSNew Drug Application for Feraccru®
9th Nov 20183:46 pmRNSHolding(s) in Company
8th Nov 20186:21 pmRNSHolding(s) in Company
1st Oct 20181:54 pmRNSNotification Of Major Holdings
1st Oct 20187:00 amRNSSubmission of an NDA for Feraccru® with the FDA
24th Sep 20181:06 pmRNSDirector/PDMR Shareholding
24th Sep 20181:02 pmRNSHolding(s) in Company
19th Sep 20187:14 amRNSLicence for the commercialisation of Feraccru
19th Sep 20187:12 amRNSInterim Results
13th Sep 20187:00 amRNSAEGIS-H2H Completion of Recruitment
26th Jul 20187:00 amRNSAppointment of Non-Executive Director
23rd Jul 20187:00 amRNSBusiness Update
9th Jul 20184:27 pmRNSHoldings in Company
9th Jul 20184:26 pmRNSHoldings in Company
28th Jun 201811:56 amRNSResult of AGM
28th Jun 20187:00 amRNSData from real-world clinical use of Feraccru
14th Jun 20187:00 amRNSPositive top-line results from AEGIS-PAED PK study
5th Jun 20187:00 amRNSDirectorate Change
5th Jun 20187:00 amRNS2017 Annual Report and 2018 AGM Notice
15th May 20186:21 pmRNSGrant of share options
4th May 20189:20 amRNSHolding(s) in Company
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.